Drug Trial Radar · NCT05872620
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,613
Actual
Start
Jun 5, 2023
Primary completion
Aug 8, 2025
Study completion Aug 8, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Conditions
- Obesity
- Overweight
- Type 2 Diabetes
Interventions
OrforglipronDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body WeightTime frame: Baseline, Week 72
Locations
136 sites in 11 countries. Site status is shown where the registry gives one.
Cahaba Research - Pelham
Pelham, Alabama
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona
Yuma Clinical Trials
Yuma, Arizona
AMCR Institute
Escondido, California
Velocity Clinical Research, Huntington Park
Huntington Park, California
Velocity Clinical Research, Westlake
Los Angeles, California
Catalina Research Institute, LLC
Montclair, California
University Clinical Investigators, Inc.
Tustin, California
Encore Medical Research
Hollywood, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
South Florida Clinical Research Institute
Margate, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Balanced Life Health Care Solutions/SKYCRNG
Lawrenceville, Georgia
Endocrine Research Solutions, Inc.
Roswell, Georgia
North Georgia Clinical Research
Woodstock, Georgia
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii
Solaris Clinical Research
Meridian, Idaho
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
MedStar Good Samaritan Hospital
Baltimore, Maryland
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan
StudyMetrix Research
City of Saint Peters, Missouri
Las Vegas Medical Research
Las Vegas, Nevada
IMA Clinical Research
Albuquerque, New Mexico
Albany Medical College, Division of Community Endocrinology
Albany, New York
Albany Stratton VA Medical Center
Albany, New York
NYC Research INC
Long Island City, New York
Accellacare - Raleigh
Raleigh, North Carolina
Summit Headlands
Portland, Oregon
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee
Velocity Clinical Research, Dallas
Dallas, Texas
Soma Clinical Trials
Denison, Texas
Epic Medical Research - DeSoto
DeSoto, Texas
Biopharma Informatic, LLC
Houston, Texas
Diabetes and Glandular Disease Center
San Antonio, Texas
VIP Trials
San Antonio, Texas
Charlottesville Medical Research
Charlottesville, Virginia
Universal Research Group
Tacoma, Washington
CONEXA Investigacion Clinica S.A.
Buenos Aires, Argentina
Centro Diabetológico Dr. Waitman
Córdoba, Argentina
Clínica Universitaria Reina Fabiola
Córdoba, Argentina
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.